13th ISTT Prize to be awarded to Dr. Alexandra Joyner

Posted by: Jan Parker-Thornburg on Tuesday, June 25, 2019

The International Society for Transgenic Technologies (ISTT, Inc.) is delighted to announce that the 13th ISTT Prize will be awarded to Dr. Alexandra Joyner for her pioneering work on homologous recombination in embryonic stem cells. The ISTT Prize is awarded to investigators who have made outstanding contributions to the field of transgenic technologies. The selection of Dr. Joyner as the 13th ISTT Prize winner was made by the ISTT Prize Committee, composed of previous ISTT prize awardees, the ISTT President, (Wojtek Auerbach), the ISTT Vice-president, (Benoit Kanzler), and the CEO of genOway (Alexandre Fraichard) . GenOway generously sponsors this prestigious award.

ISTT Letter of Support for NABR Complaint to the US Dept. of Transportation

Posted by: Tim Nottoli on Wednesday, September 26, 2018

NABR has filed an official complaint with the U.S. Department of Transportation (DOT) regarding the refusal of major airlines to carry animals for the purpose of research. Opponents to animal research have now activated their grassroots networks and are flooding the docket with individual comments.The ISTT has written a letter of support to show the DOT how critical this issue is to the future of biomedical research.

ISTT Releases Statement on 3Rs Principles as They Apply to Transgenic Technologies

Posted by: Jan Parker-Thornburg on Tuesday, February 27, 2018

Achieving the 3Rs through responsible work with animals

The ISTT is a scientific society whose members are generating and/or studying genetically modified animals and often engaged in assisted reproductive technologies. Although the use of animals is currently unavoidable we recognize that work is being done to develop alternative non-animal models in keeping with the 3Rs principle of replacement. Our membership is aware of our responsibility towards the animals we use for our work including the expectation that animal use will be reduced and the lifetime experience of experimental animals refined in accordance with the 3Rs principles of humane experimental technique.


Posted by: Ernst-Martin Füchtbauer on Thursday, October 27, 2016

The new and accelerating technical development of the CRISPR/Cas9 system opens up for the possibility of targeted genetic modifications in germline competent human embryos. This is an avenue, which until very recently has been regarded as absolutely off limits. To cross the border between genetic modifications of somatic cells and germline cells was simply not conceivable, at least in most Western countries. Indeed, the border has not yet been crossed, but we are getting closer.